Patent ID: 8821870
Filing Date: 2014-09-02
Classification: A61K,A61P,C07K

Abstract:
1. A method for delaying the progression of dry age related macular degeneration (“dry AMD”) to wet age related macular degeneration (“wet AMD”) in a patient, the method comprising the steps of: (a) selecting a patient having dry AMD in a first eye and wet AMD in a second eye, (b) preparing a biocompatible, sustained release drug delivery system comprising between about 5 μg and about 20 μg bevacizumab and a polymeric hyaluronic acid vehicle; (c) injecting the drug delivery system into the vitreous cavity of the first eye of the patient, and; (d) releasing from the drug delivery system an average of between about 14 nanograms to about 120 nanograms of the bevacizumab over a 24 hour period for a period of time between about 3 months and about 6 months, thereby preventing the progression of the dry AMD to wet AMD with the bevacizumab released from the drug delivery system.